What is RayzeBio?
Founded in 2020, RayzeBio is a biotechnology enterprise dedicated to improving patient outcomes by harnessing the power of targeted radioisotopes. The company specializes in the development of novel drug conjugates, specifically utilizing alpha-emitters like Actinium-225 to achieve precise, high-potency therapeutic delivery. By focusing on clinically validated solid tumor targets, RayzeBio addresses critical unmet needs in the oncology landscape. The firm operates at the intersection of advanced molecular biology and precision medicine, positioning itself as a pivotal player in the evolution of radiopharmaceutical drug development.
How much funding has RayzeBio raised?
RayzeBio has raised a total of $418M across 4 funding rounds:
Series A
$45M
Series B
$105M
Series C
$108M
Series D
$160M
Series A (2020): $45M with participation from Samsara Bio-Pharma, venBio Partners LLC, and Versant Ventures GmbH
Series B (2020): $105M led by Viking Global Investors, Alexandria Venture Investments, Venrock Healthcare Capital Partners, Redmile Group, Cormorant Asset Management, OrbiMed, LifeSci Venture Partners, and Logos Capital
Series C (2021): $108M supported by Versant Ventures, Cormorant Asset Management, Viking Global Investors, Vivo Capital, Samsara BioCapital, TCG X, Logos Capital, Perceptive Advisors, Deerfield Management, LifeSci Venture Partners, HealthQuest Capital, venBio Partners, OrbiMed, Redmile Group, and Alexandria Venture Investments
Series D (2022): $160M featuring Sands Capital, Viking Global Investors, Ally Bridge Group, and Wellington Management
Key Investors in RayzeBio
Versant Ventures
A global venture capital firm that partners with exceptional entrepreneurs to build and fund innovative biotechnology companies, leveraging extensive scientific and pharmaceutical expertise.
Viking Global Investors
A global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries.
OrbiMed
A specialized healthcare investment firm with deep expertise across biopharmaceuticals and medical devices, providing multi-stage capital to support innovation from early-stage to commercialization.
What's next for RayzeBio?
With the successful completion of its latest financing round, RayzeBio is well-positioned to accelerate its clinical development pipeline and expand its operational capabilities. The company is expected to leverage this capital to advance its lead candidates through rigorous clinical trials, further validating its platform's efficacy in treating complex solid tumors. As the firm transitions into a more mature stage of development, the focus will likely shift toward scaling manufacturing processes for its radioisotope conjugates and exploring strategic partnerships to broaden its therapeutic reach. The continued support from a syndicate of sophisticated healthcare investors provides the necessary runway to navigate the complexities of late-stage clinical development and regulatory approval.
See full RayzeBio company page
